Cannabidiol as a Treatment for Social Anxiety Disorder (R61)

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 11% of the time (407 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-12-03. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 17.0% (raises risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: to determineconcurrentdisordersocialtherapy
  Phrases that lowered it: randomizedtwice dailyproductsmoderateclinical
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports marked serious: 46.6% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor's past trials: 577 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Collaborators: 2 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 117 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 5.7% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Blinding: double (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD) NCT06051721 · started 2024 · scored riskier than 13% of active trials completed
• SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP) NCT01470469 · started 2012 · scored riskier than 13% of active trials completed
• Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705) NCT00725725 · started 2008 · scored riskier than 73% of active trials terminated
• Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder NCT05600114 · started 2022 · scored riskier than 11% of active trials completed
• Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo NCT04221230 · started 2020 · scored riskier than 72% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.